Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
This is a prospective phase II open-label trial, stratifying patients equally into two
cohorts consisting of carcinoid tumors and pancreatic neuroendocrine tumors (pNETs). The
purpose of this study is to test any good and bad effects of the study drug called Ibrutinib.
The study population will consist of adult patients with histologically confirmed low to
intermediate grade NETs of the GI tract, lungs and unknown primary (carcinoid tumors) or
pNETs. All patients must be confirmed to have advanced disease. The study will enroll up to
51 patients in two cohorts (30 carcinoid and 21 pNET patients).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute